Inovio Pharmaceuticals (NASDAQ:INO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) from a hold rating to a sell rating in a research report report published on Saturday.

A number of other equities research analysts also recently issued reports on INO. Royal Bank of Canada restated a "sector perform" rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright restated a "neutral" rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Finally, Oppenheimer reduced their price target on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $9.75.

Inovio Pharmaceuticals Trading Down 3.8%

NASDAQ:INO traded down $0.08 during trading hours on Friday, reaching $2.00. The company had a trading volume of 615,670 shares, compared to its average volume of 623,981. Inovio Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $12.33. The firm has a market cap of $73.35 million, a price-to-earnings ratio of -0.63 and a beta of 1.34. The firm's 50 day moving average price is $1.92 and its 200-day moving average price is $2.12.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.01 million. On average, analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP increased its holdings in shares of Inovio Pharmaceuticals by 72.9% in the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company's stock worth $5,708,000 after buying an additional 1,314,796 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $1,922,000. AIGH Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter worth about $1,197,000. Bank of America Corp DE grew its holdings in Inovio Pharmaceuticals by 1,035.2% during the 4th quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock valued at $1,173,000 after purchasing an additional 584,521 shares during the last quarter. Finally, Highbridge Capital Management LLC bought a new position in Inovio Pharmaceuticals during the 4th quarter valued at about $549,000. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.